Refining myositis associated with primary ...
Document type :
Article dans une revue scientifique: Article original
PMID :
Permalink :
Title :
Refining myositis associated with primary sjögren's syndrome: data from the prospective cohort assess
Author(s) :
Felten, Renaud [Auteur]
Giannini, Margherita [Auteur]
Nespola, Benoit [Auteur]
Lannes, Beatrice [Auteur]
Levy, Dan [Auteur]
Seror, Raphaele [Auteur]
Vittecoq, Olivier [Auteur]
Hachulla, Eric [Auteur]
Perdriger, Aleth [Auteur]
Dieude, Philippe [Auteur]
Dubost, Jean-Jacques [Auteur]
Fauchais, Anne-Laure [Auteur]
Le Guern, Véronique [Auteur]
Larroche, Claire [Auteur]
Dernis, Emmanuelle [Auteur]
Guellec, Dewi [Auteur]
Cornec, Divi [Auteur]
Sibilia, Jean [Auteur]
Mariette, Xavier [Auteur]
Gottenberg, Jacques-Eric [Auteur]
Meyer, Alain [Auteur]
Giannini, Margherita [Auteur]
Nespola, Benoit [Auteur]
Lannes, Beatrice [Auteur]
Levy, Dan [Auteur]
Seror, Raphaele [Auteur]
Vittecoq, Olivier [Auteur]
Hachulla, Eric [Auteur]

Perdriger, Aleth [Auteur]
Dieude, Philippe [Auteur]
Dubost, Jean-Jacques [Auteur]
Fauchais, Anne-Laure [Auteur]
Le Guern, Véronique [Auteur]
Larroche, Claire [Auteur]
Dernis, Emmanuelle [Auteur]
Guellec, Dewi [Auteur]
Cornec, Divi [Auteur]
Sibilia, Jean [Auteur]
Mariette, Xavier [Auteur]
Gottenberg, Jacques-Eric [Auteur]
Meyer, Alain [Auteur]
Journal title :
Rheumatology (Oxford, England)
Abbreviated title :
Rheumatology (Oxford)
Publication date :
2020-08-11
ISSN :
1462-0332
Keyword(s) :
polymyositis
inclusion body myositis
inflammatory myopathies
myositis
Sjogren's syndrome
dermatomyositis
inclusion body myositis
inflammatory myopathies
myositis
Sjogren's syndrome
dermatomyositis
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
To refine the prevalence, characteristics and response to treatment of myositis in primary SS (pSS).
The multicentre prospective Assessment of Systemic Signs and Evolution in Sjögren's Syndrome (ASSESS) cohort of 395 pSS ...
Show more >To refine the prevalence, characteristics and response to treatment of myositis in primary SS (pSS). The multicentre prospective Assessment of Systemic Signs and Evolution in Sjögren's Syndrome (ASSESS) cohort of 395 pSS patients with ≥60 months' follow-up was screened by the 2017 EULAR/ACR criteria for myositis. Extra-muscular complications, disease activity and patient-reported scores were analysed. Before enrolment and during the 5-year follow-up, myositis was suspected in 38 pSS patients and confirmed in 4 [1.0% (95% CI: 0.40, 2.6)]. Patients with suspected but not confirmed myositis had higher patient-reported scores and more frequent articular and peripheral nervous involvement than others. By contrast, disease duration in patients with confirmed myositis was 3-fold longer than without myositis. Two of the four myositis patients fulfilled criteria for sporadic IBM. Despite receiving three or more lines of treatment, they showed no muscle improvement, which further supported the sporadic IBM diagnosis. The two other patients did not feature characteristics of a myositis subtype, which suggested 'pure' pSS myositis. Steroids plus MTX was then efficient in achieving remission. Myositis, frequently suspected, occurs in 1% of pSS patients. Especially when there is resistance to treatment, sporadic IBM should be considered and might be regarded as a late complication of this disease.Show less >
Show more >To refine the prevalence, characteristics and response to treatment of myositis in primary SS (pSS). The multicentre prospective Assessment of Systemic Signs and Evolution in Sjögren's Syndrome (ASSESS) cohort of 395 pSS patients with ≥60 months' follow-up was screened by the 2017 EULAR/ACR criteria for myositis. Extra-muscular complications, disease activity and patient-reported scores were analysed. Before enrolment and during the 5-year follow-up, myositis was suspected in 38 pSS patients and confirmed in 4 [1.0% (95% CI: 0.40, 2.6)]. Patients with suspected but not confirmed myositis had higher patient-reported scores and more frequent articular and peripheral nervous involvement than others. By contrast, disease duration in patients with confirmed myositis was 3-fold longer than without myositis. Two of the four myositis patients fulfilled criteria for sporadic IBM. Despite receiving three or more lines of treatment, they showed no muscle improvement, which further supported the sporadic IBM diagnosis. The two other patients did not feature characteristics of a myositis subtype, which suggested 'pure' pSS myositis. Steroids plus MTX was then efficient in achieving remission. Myositis, frequently suspected, occurs in 1% of pSS patients. Especially when there is resistance to treatment, sporadic IBM should be considered and might be regarded as a late complication of this disease.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
CHU Lille
Inserm
Université de Lille
Inserm
Université de Lille
Submission date :
2021-07-06T12:50:22Z